A Phase II, Open-Label, Randomized Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic ER+ /HER2- Breast Cancer Resistant to Aromatase Inhibitor Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Brilanestrant (Primary) ; Fulvestrant
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms HydranGea
- Sponsors Genentech
- 15 Jan 2018 Planned End Date changed from 4 Jan 2018 to 30 Mar 2018.
- 15 Jan 2018 Planned primary completion date changed from 4 Jan 2018 to 30 Mar 2018.
- 06 Dec 2017 This trial has been completed in Germany.